DUBLIN, Jan. 30, 2020 /PRNewswire/ -- The "Gene Therapy Market by Vectors [Non-viral (Oligonucleotides), Viral (Retroviral (Gammaretroviral, Lentiviral)), Adeno-associated], Indication (Cancer, Neurological Diseases), Delivery Method (In Vivo, Ex Vivo), Region - Global Forecast to 2024" report has been added to ResearchAndMarkets.com's offering.
The global gene therapy market is projected to reach USD 13,005.6 million by 2024 from an estimated USD 3,814.9 million in 2019, at a CAGR of 27.8% during the forecast period.
This report provides a detailed picture of the global gene therapy market. It aims at estimating the size and future growth potential of the market across different segments (by vector, indication, delivery method, and region). The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
High incidence of cancer & other target diseases is a major factor driving the growth of the gene therapy market
The high incidence of cancer and other target diseases, availability of reimbursement, and the launch of new products are the major factors driving the growth of this market. In addition, the strong product pipeline of market players is expected to offer significant growth opportunities in the coming years. However, the high cost of treatment is expected to hamper the market growth to a certain extent in the coming years.
Neurological diseases segment accounted for the largest share of the gene therapy market, by indication, in 2018
Based on indication, the market is segmented into neurological diseases, cancer, hepatological diseases, Duchenne muscular dystrophy, and other indications. The neurological diseases segment accounted for the largest share of the market in 2018. This can be attributed to the increasing number of gene therapy products being approved for the treatment of neurological diseases and the high market penetration of oligonucleotide-based gene therapies.
Viral vectors segment to register the highest growth in the gene therapy market during the forecast period
The gene therapy market, by vector, has been segmented into viral and non-viral vectors. In 2018, the non-viral vectors segment accounted for the largest share of this market. However, the viral vectors segment is estimated to grow at the highest CAGR during the forecast period, primarily due to the increasing demand for CAR T-based gene therapies and the rising incidence of cancer.
North America will continue to dominate the gene therapy market during the forecast period
Geographically, the market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World. In 2018, North America accounted for the largest share of the gene therapy market, followed by Europe. Factors such as the rising prevalence of chronic diseases, high healthcare expenditure, presence of advanced healthcare infrastructure, favorable reimbursement scenario, and the presence of major market players in the region are driving market growth in North America.
Key Topics Covered
2 Research Methodology
2.1 Research Data
2.2 Secondary Data
2.2.1 Secondary Source
2.3 Primary Data
2.4 Market Size Estimation
2.4.1 Bottom-Up Approach
2.4.2 Bottom-Up Approach for Non-Viral Vectors and Viral Vectors Market
2.4.3 Growth Forecast
2.5 Market Breakdown and Data Triangulation
2.6 Assumptions for the Study
3 Executive Summary
4 Premium Insights
4.1 Gene Therapy Market Overview
4.2 North America: Market, By Vector (2018)
4.3 Geographical Snapshot of the Market
5 Market Overview
5.2 Market Dynamics
184.108.40.206 High Incidence of Cancer and Other Target Diseases
220.127.116.11 Product Approvals
18.104.22.168 Funding for Gene Therapy Research
22.214.171.124 Strong Product Pipeline
126.96.36.199 High Cost of Treatments
6 Gene Therapy Market, By Vector
6.2 Non-Viral Vectors
188.8.131.52 North America Accounted for the Largest Share of the Oligonucleotides Segment
6.2.2 Other Non-Viral Vectors
6.3 Viral Vectors
6.3.1 Retroviral Vectors
184.108.40.206 Gamma-Retroviral Vectors
220.127.116.11.1 The Availability of A Wide Range of Gamma-Retroviral Vectors Supports the Growth of This Market
18.104.22.168 Lentiviral Vectors
22.214.171.124.1 North America Accounted for the Largest Share of the Lentiviral Vectors Segment
6.3.2 Adeno-Associated Virus Vectors
126.96.36.199 Possible Applications in In Vivo Applications Have Driven Interest in Adeno-Associated Virus Vectors
6.3.3 Other Viral Vectors
7 Gene Therapy Market, By Indication
7.2 Neurological Diseases
7.2.1 Neurological Diseases Account for the Largest Share of the Market
7.3.1 Cancer is Expected to Show the Highest Growth in This Market
7.4 Hepatological Diseases
7.4.1 Increasing Prevalence of Hepatitis B Infections Will Support Market Growth
7.5 Duchenne Muscular Dystrophy
7.5.1 North America Accounted for the Largest Share of the Dmd Gene Therapy Segment
7.6 Other Indications
8 Gene Therapy Market, By Delivery Method
8.2 In Vivo Gene Therapy
8.3 Ex Vivo Gene Therapy
9 Gene Therapy Market, By Region
9.2 North America
188.8.131.52 The US Dominates the Global Market
184.108.40.206 Growing Burden of Cancer Will Support Market Growth in Canada
220.127.116.11 Germany Accounted for the Largest Share of the Market in Europe
18.104.22.168 Increasing Cancer Incidence Supports Market Growth
22.214.171.124 Rising Incidence of Melanoma Will Drive Demand in the UK
126.96.36.199 High Incidence of Targeted Diseases and Increasing Per Capita Healthcare Spending Will Drive Market Growth in Italy
188.8.131.52 Non-Viral Vectors Dominate the Spanish Market, By Vector
9.3.6 Rest of Europe
9.4 Asia Pacific
184.108.40.206 Japan Dominates the APAC Market for Gene Therapy
220.127.116.11 Rising Prevalence of Cancer and Established Base for Gene Therapy are Supportive Factors in China
9.4.3 Rest of APAC
9.5 Rest of the World
10 Competitive Landscape
10.2 Market Share Analysis, 2018
10.3 Key Strategies
10.4 Competitive Leadership Mapping (2018)
10.4.1 Visionary Leaders
10.4.3 Dynamic Differentiators
10.4.4 Emerging Companies
11 Company Profiles
11.2 Gilead Sciences, Inc.
11.3 Amgen, Inc.
11.4 Novartis AG
11.5 Orchard Therapeutics PLC
11.6 Spark Therapeutics, Inc. (A Part of Hoffmann-La Roche)
11.7 Molmed S.p.A.
11.8 Anges, Inc.
11.9 Bluebird Bio, Inc.
11.10 Human Stem Cells Institute (HSCI)
11.11 SIBIONO Genetech Co. Ltd.
11.12 Shanghai Sunway Biotech Co. Ltd.
11.13 Uniqure N.V.
11.14 Gensight Biologics S.A.
11.15 Celgene Corporation (A Bristol-Myers Squibb Company)
11.17 Sangamo Therapeutics
11.18 Mustang Bio
11.19 AGTC (Applied Genetic Technologies Corporation)
11.20 Poseida Therapeutics, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/h6pehn
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets